View More Recent Stories

Sep 26, 2019 07:10AM ContraFect (CFRX) to Present New Exebacase Data Including Late Breaker Oral Presentation at IDWeek 2019
Sep 26, 2019 07:00AM ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phas
Sep 4, 2019 05:07PM ContraFect to Present at the 2019 Janney Healthcare Conference
Aug 28, 2019 07:00AM ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
Aug 9, 2019 07:00AM ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update
Jun 3, 2019 07:00AM ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
May 31, 2019 07:00AM ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
May 10, 2019 07:00AM ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update
May 8, 2019 07:00AM ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease
Apr 16, 2019 05:15AM ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Apr 8, 2019 07:00AM ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
Apr 4, 2019 07:00AM ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Apr 2, 2019 07:00AM ContraFect Announces CEO Transition
Mar 21, 2019 07:00AM ContraFect to Present at the Bacteriophage Therapy Summit
Mar 14, 2019 07:00AM ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Mar 13, 2019 07:00AM ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference
Mar 4, 2019 07:10AM ContraFect (CFRX) Secures $6.94M in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-Negative ESKAPE Pathogens
Mar 4, 2019 07:00AM ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens
Jan 17, 2019 07:07AM ContraFect (CFRX) Reports Additional $2.3M in Funding from CARB-X to Support Gram-Negative Lysin Program
Jan 17, 2019 07:00AM ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program
Mar 30, 2017 11:00AM ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
View More Recent Stories